Syndrome News and Research

RSS

New study reveals statin therapy linked to reduced postoperative mortality

Statin drugs were first introduced to lower blood cholesterol concentrations; however, research is now discovering other benefits. A new study from France, published in the January 2011 issue of Anesthesiology, is the first to analyze the impact of preoperative chronic statin therapy on postoperative adverse events in surgical patients. Findings from the study suggest that statin therapy is associated with reduced postoperative mortality.

23 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Intellipharmaceutics International, today announced that it has notified the U.S. Food and Drug Administration that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer, for its application to market a generic of Wyeth's Protonix® tablets.

22 Dec 2010

86.9% of adults express support for melanoma genetic testing in minors

The vast majority of parents who tested positive for a genetic mutation that increases the risk of melanoma support genetic testing of their children or grandchildren.

22 Dec 2010

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

A study in this week's PLoS Medicine suggests that AIDS patients with cryptococcal meningitis who start HIV therapy are predisposed to immune reconstitution inflammatory syndrome - an exaggerated inflammatory immune response that kills up to one-third of affected people - if they have biomarkers in their blood showing evidence of a damaged immune system that is not capable of clearing the fungal infection.

22 Dec 2010

New genetic alteration predisposes individuals to Cowden syndrome

Researchers have identified a new genetic alteration that predisposes individuals to Cowden syndrome, a rare disorder that is characterized by high risks of breast, thyroid and other cancers, according to preliminary research published in the December 22/29 issue of JAMA.

21 Dec 2010

Chronic fatigue syndrome not linked to virus

The latest research from the University College London, the Wellcome Trust Sanger Institute, and University of Oxford, England suggests that chronic fatigue syndrome (CFS) is not caused by the virus XMRV (xenotropic murine leukemia virus-related virus). The team says that earlier research that linked the virus to CFS was faulty because of contamination of mouse cell DNA samples in the laboratory.

21 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

Hemispherx Biopharma, Inc. announced that the Company has entered into an agreement with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA for the marketing of Alferon N Injection®, the Company's natural interferon injection product which has been FDA approved for a category of sexually transmitted diseases in Argentina with an option for other Latin American countries upon receipt of those respective countries' regulatory approval for any use of the product.

21 Dec 2010

FDA warns against consumption of Sally Jackson cheese due to risk of E. coli O157:H7

The FDA, in cooperation with other state and local public health agencies, is warning consumers not to eat any Sally Jackson cheeses. The products were processed under conditions that create a significant risk of contamination of the unpasteurized raw milk and finished cheese, and Sally Jackson cheeses have been identified as one possible source of eight cases of E. coli O157 infections in an ongoing investigation.

20 Dec 2010

Researchers examine socio-economic consequences of hypersomnia

Danish sleep researchers at the University of Copenhagen and the Danish Institute for Health Services Research have examined the socio-economic consequences of the sleep disorder hypersomnia in one of the largest studies of its kind.

20 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Collaboration seeks to uncover the best strategies to improve health care, lower costs

A group of health care organizations are joining forces to compile evidence on the strategies the work best to address a variety of common, and usually expensive, medical conditions. Meanwhile, the nation's new Medicare chief is hitting the road to hear ideas about improving the health care system.

17 Dec 2010

FDA recommends removal of breast cancer indication from Avastin label

The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

17 Dec 2010

Researchers begin placebo-controlled trial to test drug treatment for Rett syndrome

Researchers at Children's Hospital Boston have begun a randomized, placebo-controlled trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of autism in girls.

16 Dec 2010

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

Discovery Laboratories, Inc. today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).

16 Dec 2010

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

Miracor Medical Systems GmbH announced today that the company has received CE-mark for the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, designed to improve acute coronary syndrome (ACS) revascularization following primary percutaneous coronary intervention (PCI).

16 Dec 2010

SIDS deaths surge 33% on New Year's Day

Not a happy holiday thought, but an important one: The number of babies who die of SIDS, or sudden infant death syndrome, surges by 33 percent on New Year's Day. The suspected reason? Alcohol consumption by caretakers the night before.

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

Syndrome News and Research

New study reveals statin therapy linked to reduced postoperative mortality

Top ten advances in cardiovascular, stroke research in 2010

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

86.9% of adults express support for melanoma genetic testing in minors

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

New genetic alteration predisposes individuals to Cowden syndrome

Chronic fatigue syndrome not linked to virus

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

FDA warns against consumption of Sally Jackson cheese due to risk of E. coli O157:H7

Researchers examine socio-economic consequences of hypersomnia

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Collaboration seeks to uncover the best strategies to improve health care, lower costs

FDA recommends removal of breast cancer indication from Avastin label

Researchers begin placebo-controlled trial to test drug treatment for Rett syndrome

Discovery Labs awarded NIH Fast Track SBIR grant for developing aerosolized KL4 surfactant for RDS

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

SIDS deaths surge 33% on New Year's Day

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News